Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holland, K. D.
Right arrow Articles by Glauser, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holland, K. D.
Right arrow Articles by Glauser, T. A.
Related Collections
Right arrow All Pediatric
Right arrow Antiepileptic drugs
Right arrow Partial seizures
NEUROLOGY 2007;69:596-599
© 2007 American Academy of Neurology

Response to carbamazepine in children with newly diagnosed partial onset epilepsy

Katherine D. Holland, MD, PhD and Tracy A. Glauser, MD

From the Department of Neurology, Cincinnati Children's Hospital Medical Center, OH.

Address correspondence and reprint requests to Dr Holland, Department of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229 Katherine.holland{at}cchmc.org

Objective: The purpose of this work is to characterize the effectiveness and therapeutic doses of carbamazepine (CBZ) in children with localization-related epilepsy.

Methods: Treatment to initial CBZ monotherapy and doses associated with 1-year seizure freedom were examined in 100 consecutive children with partial epilepsy.

Results: Of the 100 patients studied, 55 became seizure-free on CBZ monotherapy, 10 did not tolerate CBZ within the first 3 months of therapy owing to either hypersensitivity or intolerable side effects, and 35 continued to have seizures. In children age <12, over 95% responded at doses below 17.5 mg/kg/day; in children age >12, over 95% responded at below 15 mg/kg/day.

Conclusions: We suggest that other antiepileptic treatments be considered when seizures continue in children taking carbamazepine doses between 15 and 17.5 mg/kg/day even if side effects are absent.

Supported by grants from the Cincinnati Children's Hospital Medical Center Trustees and the NIH (NS044956).

Disclosure: The authors report no conflicts of interest.

Received October 16, 2006. Accepted in final form March 12, 2007.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.